Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IRWD, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Lesinurad FDA approved Dec 2015 · Zurampic (discontinued) |
Gout | Phase 4 · NCT03226899 | Terminated |
| Therapeutic Corticosteroid | Gout | Phase 4 · NCT03226899 | Terminated |
| Standard-dose PPIs QD | Gastroesophageal Reflux Disease (GERD) | Phase 3 · NCT03561090 | Terminated |
| Functional Constipation (FC) participants… | Irritable Bowel Syndrome With Constipation | Phase 3 · NCT04166058 | Completed |
| Irritable Bowel Syndrome with Constipation… | Irritable Bowel Syndrome With Constipation | Phase 3 · NCT04166058 | Completed |
| IW-3718 | Gastroesophageal Reflux Disease (GERD) | Phase 3 · NCT03561090 | Terminated |
| Proton Pump Inhibitor | Gastroesophageal Reflux Disease | Phase 2 · NCT02637557 | Completed |
| MD-7246 | Irritable Bowel Syndrome With Diarrhea (IBS-D) | Phase 2 · NCT03931785 | Completed |
| Linaclotide Acetate | Constipation | Phase 2 · NCT00306748 | Completed |
| MD-0727 | Hypercholesterolemia | Phase 2 · NCT00404001 | Completed |
| IW-6118 | Healthy | Phase 2 · NCT01107236 | Completed |
| IW-3300 rectal foam | Interstitial Cystitis | Phase 2 · NCT05740007 | Terminated |
| IW-9179 | Diabetic Gastroparesis | Phase 2 · NCT02289846 | Completed |
| Microgestin® | Healthy Volunteers | Phase 1 · NCT03856970 | Completed |
| Levothyroxine | Healthy Volunteers | Phase 1 · NCT03856970 | Completed |
| IW-3300 | Healthy Volunteers | Phase 1 · NCT05362695 | Completed |
Also used in these trials (approved or third-party drugs, not IRWD's own candidates): Allopurinol, Linaclotide, Colchicine, Naproxen Sodium 220Mg, Glyburide, Digoxin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IRWD holds $86.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IRWD files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | Institution (13G, 5%+) | 15,000,000 | 9.06% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 13,373,568 | 8.08% | 2026-06-30 |
| Thomas A MCCOURT Chief Executive Officer, Director |
Insider | 1,898,838 | 1.15% | 2026-03-10 |
| Mark G Currie Director |
Insider | 676,900 | 0.41% | 2026-06-16 |
| Michael Shetzline SVP, CMO, Head-Res&Drug |
Insider | 658,037 | 0.40% | 2026-03-10 |
| Minardo John Chief Legal Officer |
Insider | 500,498 | 0.30% | 2026-03-10 |
| Tammi L Gaskins Chief Commercial Officer |
Insider | 350,350 | 0.21% | 2026-03-10 |
| Alexander J Denner Director |
Insider | 327,549 | 0.20% | 2026-09-15 |
| Ronald Silver PFO & PAO |
Insider | 313,680 | 0.19% | 2026-07-07 |
| Gregory S. Martini Chief Financial Officer |
Insider | 297,213 | 0.18% | 2026-03-10 |
| Jon R Duane Director |
Insider | 253,820 | 0.15% | 2026-06-16 |
| Julie McHugh Director |
Insider | 250,749 | 0.15% | 2026-06-16 |
Share count 165,550,760 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IRWD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →